"Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program. Click to show full abstract

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Keywords: oncology; food drug; accelerated approval; drug administration; exposure

Journal Title: JAMA Oncology
Year Published: 2023

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
3

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended